Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion
An Exploratory, Randomized, Double-Blind, Placebo-Controlled and Open-label Extension Study of the Safety, Tolerability, and Efficacy of Arbaclofen in Subjects With 16p11.2 Deletion
Sponsor: Clinical Research Associates, LLC
A PHASE2 clinical study on 16P11.2 Deletion Syndrome, this trial is ongoing. The trial is conducted by Clinical Research Associates, LLC and has accumulated 9 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
May 2023 — Jun 2024 [monthly]
Recruiting PHASE2
-
Mar 2023 — May 2023 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Sep 2022 — Mar 2023 [monthly]
Recruiting PHASE2
Status: Suspended → Recruiting
-
Sep 2021 — Sep 2022 [monthly]
Suspended PHASE2
Status: Not Yet Recruiting → Suspended
-
Jan 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Clinical Research Associates, LLC
For direct contact, visit the study record on ClinicalTrials.gov .